33763-20-1

Basic information

• Product Name: 4-METHYL-2-PHENYL-1,3-THIAZOLE-5-CARBOXYLIC ACID
• Synonyms: 4-METHYL-2-PHENYL-THIAZOLE-5-CARBOXYLIC ACID;4-METHYL-2-PHENYL-1,3-THIAZOLE-5-CARBOXYLIC ACID;AKOS BBS-00004452;IFLAB-BB F1912-0027;4-Methyl-2-phenyl-5-thiazolecarboxylicacid;4-Methyl-2-phenyl-1,3-thiazole-5-carboxylic acid ,97%;4-Methyl-2-phenyl-1,3-thiazole-5-carboxylic acid, Tech.;5-Carboxy-2-phenylthiazole
• CAS NO: 33763-20-1
• Molecular Formula: C₁₁H₉NO₂S
• Molecular Weight: 219.26
• Mol File: 33763-20-1.mol
• Article Data: 11

Chemical Properties

• Melting Point: 210-212°C
• Boiling Point: 424 °C at 760 mmHg
• Flash Point: 210.3 °C
• Appearance: /
• Density: 1.319 g/cm³
• Vapor Pressure: 6.02E-08mmHg at 25°C
• Storage Temp.: 2-8°C
• PKA: 1.20±0.37(Predicted)
• CAS DataBase Reference: 4-METHYL-2-PHENYL-1,3-THIAZOLE-5-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-METHYL-2-PHENYL-1,3-THIAZOLE-5-CARBOXYLIC ACID(33763-20-1)
• EPA Substance Registry System: 4-METHYL-2-PHENYL-1,3-THIAZOLE-5-CARBOXYLIC ACID(33763-20-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 22-26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 33763-20-1(Hazardous Substances Data)

Usage

Chemical Properties

White solid

Uses

4-Methyl-2-phenyl-1,3-thiazole-5-carboxylic Acid is a useful reagent in Pd-catalyzed decarboxylative C-H cross-coupling of oxazoles and thiazoles.

InChI:InChI=1/C11H9NO2S/c1-7-9(11(13)14)15-10(12-7)8-5-3-2-4-6-8/h2-6H,1H3,(H,13,14)/p-1

Upstream product

• 2227-79-4 benzenecarbothioamide 
• 609-15-4 ethyl 2-chloro-3-oxo-butyrate 
• 53715-64-3 4-methyl-2-phenyl-thiazole-5-carboxylic acid ethyl ester 
• 80269-25-6 2-Phenyl-4-methyl-thiazol-5-yl-glykolsaeure 
• 7520-94-7 5-acetyl-4-methyl-2-phenylthiazole 
• 80269-16-5 2-Phenyl-4-methyl-5-glyoxyloyl-thiazol 
• 54001-18-2 4-methyl-2-phenyl-thiazole-5-carbonyl chloride 
• 55-21-0 benzamide 

Downstream Products

• 1069135-29-0 C₂₇H₂₇N₃O₃S₂ 
• 1198119-04-8 C₂₈H₂₆N₂O₃S₂ 
• 1227747-42-3 C₁₉H₂₀N₂O₃S 
• 1227747-45-6 C₂₁H₁₈N₂O₃S₂ 
• 1227747-48-9 C₁₉H₁₄N₂OS 
• 1227747-46-7 C₂₇H₂₂N₂O₄S₂ 
• 1227747-44-5 C₂₃H₁₉N₃O₆S 
• 1227747-49-0 C₁₉H₁₃ClN₂OS 
• 1227747-41-2 C₁₇H₁₆N₂O₃S 
• 1227747-43-4 C₁₉H₂₀N₂O₃S 
• 1227747-39-8 2-(4-methyl-2-phenyl-thiazol-5-yl)-5-phenyl-oxazole-4-carboxylic acid ethyl ester 
• 1227747-40-1 C₂₄H₂₀N₂O₆ 
• 1227747-47-8 C₁₆H₁₄N₂O₃S 
• 1368189-81-4 4-methyl-2-phenylthiazole-5-carbothioamide 

Relevant articles and documents

Thiazole hydrazide compound as well as preparation method and application thereof

The invention relates to a thiazole hydrazide compound as well as a preparation method and application thereof. The compound has the structure shown by the general formula (I). The compound has a good inhibition effect on pathogenic fungi and bacteria, an

Structure-activity relationships of thiazole and benzothiazole derivatives as selective cannabinoid CB2 agonists with in vivo anti-inflammatory properties

The strong therapeutic potential of CB2 receptor agonists for use as anti-inflammatory agents that lack psychiatric side effects has attracted substantial interest. We herein describe the rational design and synthesis of novel thiazole and benzothiazole derivatives and the evaluation of their binding affinity and functional activity on CB1 and CB2 receptors. The series with the general formula N-(3-pentylbenzo [d]thiazol-2(3H)-ylidene) carboxamide (compounds 6a-6d) exhibited the highest affinity and selectivity towards CB2 receptors with Kis in the picomolar or low nanomolar range, and selectivity indices (Ki hCB1/Ki hCB2) reaching up to 429 fold. Notably, these compounds also demonstrated an agonistic functional activity in cellular assays with EC50s in the low nanomolar range. More interestingly, compound 6d, the 3-(trifluoromethyl)benzamide derivative, exhibited remarkable protection against DSS-induced acute colitis in mice model.

Design, synthesis and evaluation of aromatic heterocyclic derivatives as potent antifungal agents

To further enhance the anti-Aspergillus efficacy of our previously discovered antifungal lead compounds (1), a series of aromatic heterocyclic derivatives were designed, synthesized and evaluated for in vitro antifungal activity. Many of the target compounds showed good inhibitory activity against Candida albicans and Cryptococcus neoformans. In particular, the isoxazole nuclei were more suited for improving the activity against Aspergillus spp. Among these compounds, 2-F substituted analogues 23g and 23h displayed the most remarkable in vitro activity against Candida spp., C. neoformans, A. fumigatus and fluconazole-resistant C.alb. strains, which is superior or comparable to the activity of the reference drugs fluconazole and voriconazole. Notably, the compounds 23g and 23h exhibited low inhibition profiles for various isoforms of human cytochrome P450 and excellent blood plasma stability.